

March 7, 2018



Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- **Actinium Pharmaceuticals, Inc.** (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30th Annual ROTH Conference being held on March 11-14, 2018 at the Ritz Carlton in Dana Point, California. Details of Actinium's presentation are as follows:

Date: Tuesday, March 13, 2018

Time: 11:00 AM PT

Room: Yellow – Salon 6

Venue: The Ritz Carlton Hotel

Management will conduct 1-on-1 meetings with investors during the conference. To arrange a meeting with Actinium please contact, Steve O'Loughlin, Actinium's Principal Financial Officer at soloughlin@actiniumpharma.com.

About 30th Annual ROTH Conference

30th Annual ROTH Conference scheduled for March 11-14, 2018 at The Ritz Carlton, Laguna Niguel in Orange County, CA. Following the success of the previous year's events, the ROTH Conference, with close to 550 participating companies and over 4,700 attendees, will feature presentations from public and private companies in a variety of sectors including:

- Business Services
- Cleantech, Industrial Growth & Solar
- Consumer
- Healthcare
- Resources: Oil & Gas / Metals & Mining
- Technology, Internet & Media

This gathering of institutional investors, private equity investors, VCs and executives, and service providers has become a must-attend event for anyone working in the small and mid-cap space.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. Our targeted therapies have demonstrated the potential to result in significantly improved access to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival. Our targeted therapies are ARC's or Antibody

Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. We have four clinical trials based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the isotope Actinium-225 (Ac²²⁵) which emits alpha particles. In addition, our most advanced product candidate, lomab-B, an ARC developed by the Fred Hutchinson Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131. We are currently conducting a pivotal Phase 3 trial of lomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow transplant is a potentially curative treatment for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders. lomab-B has been tested in several of these other cancers with over five hundred patients treated in several Phase 1 and 2 trials with promising results. Upon successful completion of our Phase 3 clinical trial for lomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug. We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Our most advanced CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy. Actimab-A also has Orphan Drug designation in the US and EU. Actimab-M, our second CD33 program ARC, is being studied in a Phase 1 trial for patients with refractory multiple myeloma. Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have a p53 genetic mutation. Our Phase 1 trial studying Actimab-A with CLAG-M is our fourth CD33 program clinical trial for patients with relapsed or refractory AML. Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial Sloan Kettering Cancer Center, is focused on leveraging Actinium's know how and intellectual property to create additional ARC drug candidates by labeling Ac²²⁵ to targeting moieties that we will either progress in clinical trials ourselves or out-license.

More information is available at www.actiniumpharma.com and our Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly

reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contact:

Actinium Pharmaceuticals, Inc.

Steve O'Loughlin

Principal Financial Officer

soloughlin@actiniumpharma.com

Investor Relations

Marek Ciszewski, J.D.

949.574.3860

ATNM@liolios.com



Source: Actinium Pharmaceuticals